DNAH11: A Potential Drug Target and Biomarker (G8701)

Target Name: DNAH11

NCBI ID: G8701

DNAH11

DNAH11: A Potential Drug Target and Biomarker

Introduction

DNAH11, also known as dynein, axonemal, and heavy polypeptide 11, is a protein that plays a crucial role in the structure and function of cilia, which are tiny hair-like structures that line the airways of the body. Mutations in the DNAH11 gene have been linked to various respiratory and neurological disorders, making it an attractive target for drug development. In this article, we will explore the potential drug target and biomarker properties of DNAH11.

The Importance of Cilia

Cilia are essential for maintaining healthy respiratory and digestive systems. They are composed of several layers of thin protein molecules that vibrate in a coordinated manner to keep the airways and gut lining clear of particles and pathogens. In the human body, cilia help to filter out about 99% of the air we breathe, and they also play a key role in the digestion of food.

Mutations in DNAH11 gene

Mutations in the DNAH11 gene have been linked to various respiratory and neurological disorders, including chronic obstructive pulmonary disease (COPD), asthma, and progressive familial intrahepatic cholestasis (PFIC). These mutations have been shown to alter the structure and function of the cilia, leading to the production of abnormal or missing cilia that contribute to the development of these disorders.

DNAH11 as a Drug Target

The potential drug target for DNAH11 is based on its role in the structure and function of cilia. By targeting the DNAH11 gene, drugs can potentially improve the function of cilia and alleviate the symptoms associated with genetic mutations that affect cilia.

One approach to targeting DNAH11 is to use small molecules that can modulate the activity of the cilia. For example, drugs that inhibit the activity of the cilia-associated protein ECT can potentially reduce the amount of air that is filtered out by the cilia, leading to symptoms such as coughing and shortness of breath.

Another approach to targeting DNAH11 is to use antibodies that specifically target the protein. These antibodies can be used to visualize the protein in the cilia and determine its levels. By monitoring the levels of DNAH11 in the cilia, researchers can determine if the drug is having its intended effect.

DNAH11 as a Biomarker

In addition to its potential as a drug target, DNAH11 has also been shown to be a useful biomarker for various respiratory and neurological disorders. The levels of DNAH11 in the cilia can be affected by a variety of factors, including genetic mutations, infections, and exposure to environmental toxins.

Research has shown that abnormal levels of DNAH11 in the cilia can contribute to the development of chronic obstructive pulmonary disease (COPD), asthma, and PFIC. For example, studies have shown that individuals with mutations in the DNAH11 gene are more likely to have these disorders, and that treatment with drugs that modify the function of the cilia can improve symptoms in these individuals.

Conclusion

In conclusion, DNAH11 is a protein that plays a crucial role in the structure and function of cilia. Mutations in the DNAH11 gene have been linked to various respiratory and neurological disorders, making it an attractive target for drug development. The potential drug target for DNAH11 is based on its role in the structure and function of cilia, and the use of small molecules or antibodies to modulate its activity. DNAH11 can also be used as a biomarker for the development

Protein Name: Dynein Axonemal Heavy Chain 11

Functions: Force generating protein of respiratory cilia. Produces force towards the minus ends of microtubules. Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP

The "DNAH11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAH11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets